All players in the healthcare market understand that the old model of the pharmaceutical industry, which has traditionally focused on developing molecules and promoting new drugs with the support of teams of sales representatives, will no longer be tenable in the near future.
Technology companies, including digital startups, have introduced health services based on the use of AI, microchips and cloud computing. The resulting monitoring solutions are the best for patients suffering from chronic diseases. Such solutions can effectively help patients manage the disease and provide a significant improvement in quality of life.
The digitally-driven transformation in health
In the era of digital health, the patient journey will be significantly transformed due to the use of AI at the monitoring and decision making stages. As a result, personal communication with a physician will become less relevant in the medical treatment and health maintenance. And a digital platform will become almost more important than medical treatment.
For example, in the treatment of diabetes insulin delivery systems, insulin pumps and devices for continuous monitoring of blood glucose are no less important than the insulin that a diabetes sufferer uses. Add to that the fact that effective control of type 2 diabetes, by following a proper diet and increasing physical activity, can make it possible to live without pills.
A virtual opportunity for expanding the value chain
Companies are beginning to invest more and more funds in digital health. Big pharma does not want to dwell in the digital world, but they also have begun to play in this market. This is the next logical step in the evolution, because pharmaceutical companies have vast expertise in disease, in the patient and health in general. So it seems that big pharma has the opportunity to significantly expand the value chain beyond just developing and promoting medicines.
In the new digital reality,

View Entire Article on GFK.com